Anavex Life Sciences CORP Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Vanguard Capital Management has reported beneficial ownership of 5.03% of Anavex Life Sciences Corp. common stock as of June 30, 2026.
NASDAQ
The Vanguard Group filed an amendment to its Schedule 13G for Anavex Life Sciences Corp., reporting zero beneficial ownership following an internal realignment.